Thesethree stocks have struggled lately butthat could make today an exciting entry point for long-term investors, especially those who relishdividends.
AstraZeneca
Pharmaceutical stocks are often seen as the old reliables of investing, but AstraZeneca (LSE: AZN) involvestaking a bit of a punt. The gambleis this: youre banking on chief executivePascal Soriots strategy of replenishing the companys pipeline of drugs faster than itcan be drainedby patent expiries and generic competition.
The impact of patent expiries is real and immediate: sales of its big sellingheart drug Crestor are already declining in advance of its US patent expiry next month. The pipeline, by contrast, has yet to start flowing. Soriotreckons that new blockbuster treatments candeliver revenues of $45bn by 2023, up from$26bn last year, but thats seven longyears away. AstraZeneca is (quite rightly) pumping money into R&D, with corecosts rising 21% in the last year, and all investors can do is hope it pays off, or risk losing their shirt.Are youcontent with a 4.52% yield while waiting to see if Soriots high stakes flutterplays out?
Old Mutual Group
This is a troubled time for life companies as global stock market volatility unnerves investors, and Old Mutual Group (LSE: OML) can hardly have expected to escape unscathed, especially given its focus on emerging markets. Its share price is down 20% over the past year but it has revived lately in line with broader investor confidence, to rise 25% in three months.
To complicate matters, the board announced a major restructuring programme in March, which will separate the groups four constituent businesses. This could be bad news for dividend investors. Payouts may be limited as the company looks to retain more capital to cushionthe separation process, which should be completed towards the end of 2018. Group chief executive Bruce Hemphill says this should make it easier for each component to raise finance from capital markets, manageregulatory demands and release shareholder value. Once again, investors will have to be patient. Trading at 10 times earnings and yielding 4.53%, the pricelooks right for a company thatreported pre-tax operating profit growth of 11% to 1.7bn in 2015.
Standard Life
Fellow insurer Standard Life (LSE: SL) has also had a rough 12 months, falling 27% in that time, but in contrast to OldMutualthere has been no bounce back lately, as its share price continues to fall. Yet it may also feel unfairly treated by stock markets, with 2015 results showing a solid 4% rise in assets under administration to 307.4bn despite volatile markets,driven by net inflows of 6.3bn.
It was able to reward loyal investors with total dividends of18.36p, up 7.8% for the year, and today it yields a handsome 5.38%. Its valuation looks pricey today at 25 times earnings, but is forecast to fall to just 12.6times by year end, due to anticipated earnings per share growth of 99% this year. Dont be confused by its name: Standard Life is less of an insurer, more of anasset manager these days. HSBC has set a buyprice of490p which would suggest almost 45% upside from todays 341p. Only a stock market crash can stop it now.
If you’re looking for a top dividend stock with great prospects then check out our NEW report A Top Income Share from The Motley Fool.
While many leading UK companies are slashing their dividends, this FTSE 250 star accelerated its payout at astonishing speed in 2015.
The Fool’s crack team of analysts is so impressed by this company’s ambitious growth plans they’re happy to call it one of the best income stocks on the market today.
Click here to enjoy this FREE, no-obligation wealth report. It will be yours in moments and won’t cost you a penny.
Harvey Jones has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca. We Fools don’t all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.
